Abstract
Mutations in PAX6 are involved in several developmental eye disorders. These disorders have considerable phenotypic variability, ranging from panocular forms of congenital aniridia and microphthalmia to isolated anomalies of the anterior or posterior segment. Here, we describe 3 families with variable inter-generational ocular expression of aniridia, iris coloboma, or microphthalmia, and an unusual transmission of PAX6 mutations from an unaffected or mildly affected parent; all of which raised suspicion of gonosomal mosaicism. We first identified two previously known nonsense mutations and one novel likely pathogenic missense variant in PAX6 in probands by means of targeted NGS. The subsequent segregation analysis by Sanger sequencing evidenced the presence of highly probable mosaic events in paternal blood samples. Mosaicism was further confirmed by droplet digital PCR analysis in several somatic tissues of mosaic fathers. Quantification of the mutant allele fraction in parental samples showed a marked deviation from 50%, with a range between 12 and 29% depending on cell type. Gonosomal mosaicsm was definitively confirmed in one of the families thanks to the availability of a sperm sample from the mosaic father. Thus, the recurrence risk in this family was estimated to be about one-third. This is the first report confirming parental PAX6 mosaicism as a cause of disease recurrence in aniridia and other related phenotypes. In addition, we demonstrated that post-zygotic mosaicism is a frequent and underestimated pathogenic mechanism in aniridia, explaining intra-familial phenotypic variability in many cases. Our findings may have substantial implications for genetic counseling in congenital aniridia. Thus, we also highlight the importance of comprehensive genetic screening of parents for new sporadic cases with aniridia or related developmental eye disease to more accurately assess recurrence risk. In conclusion, somatic and/or gonosomal mosaicism should be taken into consideration as a genetic factor to explain not only families with unaffected parents despite multiple affected children but also variable expressivity, apparent de novo cases, and even uncharacterized cases of aniridia and related developmental eye disorders, apparently lacking PAX6 mutations.
Introduction
PAX6 encodes a highly conserved homeodomain-containing transcription factor that plays pivotal roles in normal ocular and neural development (). Dominant PAX6 mutations lead to a spectrum of ocular developmental anomalies (ODAs) depending on the mutation type and gene dosage (). PAX6 haploinsufficiency, which results from loss-of-function variants or 11p13 microdeletions involving this gene or their 5′ regulatory regions, is the major cause of congenital aniridia (MIM# 106210) (). By contrast, missense mutations usually exhibit a moderate impact on PAX6 functionality and are often associated with some atypical PAX6-associated phenotypes, such as mild forms of iris coloboma or isolated foveal hypoplasia, or more severe phenotypes of Peter’s anomaly and microphthalmia (; ; ; ; ). However, no obvious genotype-phenotype correlations have been established to date (; ; ; ).
Aniridia, characterized by the incomplete development of the iris and fovea, is the most frequent PAX6-related condition, with a worldwide incidence of 1:50,000–100,000 births (). Patients exhibit photophobia, low visual acuity, and nystagmus. Phenotypic variability is commonly observed (). Iris hypoplasia may manifest as a complete absence of the iris (or “aniridia”) but also may present with minor structural iris defects, leading to atypical iris coloboma, iris holes, or stromal hypoplasia (), symptoms which can be only recognizable on slit-lamp examination. Additionally, a wide range of abnormalities in the cornea, anterior chamber, lens, and optic nerve have been reported conferring a higher risk in patients for secondary glaucoma, cataracts, and aniridia-associated keratopathy (AAK), which further worsen the visual outcome (). Inter-familial and intra-familial variability on disease onset and severity of these secondary symptoms manifesting as congenital, childhood, or even adult forms are also observed (; ). However, the molecular mechanisms underlying the variable expressivity of the PAX6 mutations have yet to be elucidated. Identifying and understanding the genetic mechanisms that affect the severity of the disease is essential to provide a more accurate diagnosis and better clinical management of PAX6-associated disorders.
Somatic or gonosomal mosaicism might explain part of the phenotypic variability and/or reduced penetrance in aniridia, similarly to that reported in other dominant ocular disorders (; ). Post-zygotic variants (PZV), arising as errors in DNA replication at early embryonic stages, have recently been revealed as a novel source of de novo and somatic mosaic variants thanks to the advent of more sensitive genotyping technologies (, ). The developmental stage at which PZVs arise has a major influence on their frequency and distribution in affected tissues and thus on phenotypic expressivity and the recurrence risk in offspring (). Interestingly, recent studies have showed that PZVs could account for up to 10% of rare neurodevelopmental disorders such as intellectual disability, epilepsy, and autism (; ; ); therefore, mosaicism may be underestimated in sporadic cases of other developmental diseases.
In aniridia, up to two-thirds of patients are sporadic (; ) and thought to carry de novo mutations that are generally not detected in parental blood samples. Nevertheless, germline or even low-level somatic mosaicism in one of the parents cannot be ruled out, as multiple tissues are not usually tested during genetic screening. Germline mosaicism has long been postulated in PAX6-related disorders to explain the disease co-occurrence in several affected siblings with no family history of eye disorders (; ; ; ). However, to our knowledge, PAX6 mosaicism has never been reliably confirmed in a suspected family, mainly due to technical limitations in genetic testing and/or constraints on the availability of germinal or somatic DNA samples other than blood. To date, only a small number of exceptional cases of somatic mosaicism for 11p13 microdeletions have been reported in aniridia (; ; ).
Here, we identify parental mosaicism in three families with PAX6-related ODAs in which gonosomal PZVs have been accurately assessed through quantitative droplet-digital PCR (ddPCR). Detection of mosaicism was very relevant to these families in terms of genetic counseling, which allowed for more accurate determination of the risk of recurrence in future offspring. Remarkably, our findings also highlight the inter-generational variable expressivity in these families, which seems to be clearly explained by the presence of parental mosaic PAX6 mutations as well as by the further transmission of these mutations to the offspring. Thus, our work confirms that mosaicism is an underestimated cause of phenotypic variability and disease recurrence in aniridia and other PAX6-related ODAs.
Materials and Methods
Patients
We studied a cohort of 247 unrelated Spanish families with ODAs consisting of 78 with congenital aniridia, 33 with anterior segment dysgenesis and 136 with other PAX6-related phenotypes, i.e., ocular coloboma, microphthalmia, isolated foveal or optic nerve hypoplasia. Patients and affected and healthy relatives were recruited from two public hospitals from Madrid (Spain), Fundación Jiménez Díaz University Hospital and University Hospital Ramón y Cajal. Genomic DNA was obtained from peripheral blood, saliva, urine, and sperm using standard procedures.
This study was designed in compliance with the tenets of the Helsinki Declaration, and patient enrollment was approved by the ethics committees of both institutions. All participants or their legal guardians provided written informed consent prior to their participation in this study.
Molecular Screening
Probands were screened according to a previously reported genetic algorithm for molecular diagnosis of PAX6 defects (). Pathogenic PAX6 variants were screened by Sanger or next-generation sequencing (NGS). 11p13 microdeletions were studied by MLPA and/or custom CGH-arrays, as previously reported ().
The proband of Family 1 was screened using a customized 151-gene panel (unpublished data). Both probands of Families 2 and 3 were studied by means of a custom 260-gene panel, as previously described (). Briefly, library capture of all coding and non-coding exons and 20 bp of intronic boundaries was performed using HaloPlex or SureSelect QXT technologies (Agilent Technologies, Santa Clara, CA, United States). Massive sequencing was carried out using Illumina MiSeq or NextSeq 500 platforms running on paired-end mode at a minimum of 450X.
Bioinformatic analysis was performed using standard procedures and custom in-house pipelines for mapping, variant calling, and annotation. Pathogenicity prediction of missense variants was performed using CADD1, M-CAP2, and Alamut software (Interactive Biosoftware, France), which includes SIFT, Polyphen, MutationTaster, and Align GVGD. Population frequencies of the detected variants were assessed using gnomAD3 and CIBERER Spanish Variant Server4. Variants were also searched in the literature and in the PAX6 database5. All variants detected by NGS were validated by Sanger sequencing using specifically designed primers (Available On Request). The mutation nomenclature was referred to the canonical RefSeq PAX6 isoform NM_000280.4.
SNaPshot Assays
Amplified PAX6 exons 5, 6, and 10 were analyzed for the presence of c.120C>A, c.178T>C, and c.771G>A variants using the ABI Prism SNaPshot Multiplex kit (Themo Fisher). Reactions were performed in a 20 μL mix containing 3 μL purified PCR amplicons, 3 μL SNaPshot Ready Multiplex Ready Reaction Mix, and 0.4 μM of specific primers. Single base extension and further post-extension SAP treatment were performed following the manufacturer’s protocol. Labeled products were separated on an ABI3130xl Genetic Analyzer and analyzed with GeneMapper v4 software.
ddPCR
Custom or commercial TaqMan SNP Genotyping Assays (Thermo Fisher) were used for genotyping the PAX6 variants c.120C>A, c.178T>C, and c.771G>A (rs121907929; commercial Assay ID: C_152371166_10). DNA samples were evaluated by ddPCR using the Droplet Digital PCR QX200 System (Bio-Rad Laboratories, Hercules, United States) in a 20 μL PCR mix containing 10 μL 2x ddPCR Supermix for probes (Bio–Rad), 900 nM target-specific PCR primers, 250 nM FAM-labeled (mutant–allele) probe, and 250 nM VIC-labeled (wild–type allele) probe. Droplet emulsion was thermally cycled on a C1000 Touch Thermal Cycler (Biorad) in the following conditions: denaturing at 95°C for 10 min, 40 cycles of PCR at 94°C for 30 s, and a single step of annealing/extension at 56.4°C for 1 min, and a final step to deactivate enzyme at 98°C for 10 min. Each sample was run in quadruplicate. Data were analyzed using Quantasoft v1.7 software (Bio-Rad) using Rare Event Detection settings.
Results
Detection of Parental Mosaicism in PAX6
We investigated the presence of parental mosaicism associated with disease-causing PAX6 variants in 3 families from a large cohort of Spanish patients with aniridia (n = 78) and other ODAs (n = 169). First, heterozygous PAX6 variants were identified in probands of these 3 families through targeted NGS using custom approaches for PAX6 screening. We found the previously reported nonsense variants c.120C>A;p.(Cys40∗) and c.771G>A;p.(Trp257∗) (; ) in 2 probands with aniridia, and a novel likely pathogenic missense variant, c.178T>C;p.(Tyr60His), in a proband with non-syndromic microphthalmia. This last variant in the paired domain of PAX6 affected a highly conserved tyrosine residue (GERP ++ score 5.4 and PhyloP score 9.3), was predicted to be pathogenic by all in silico tools, had not been publicly reported in population and mutation databases, and segregated dominantly in two consecutive generations of affected individuals.
The occurrence of germinal or gonosomal mosaicism was suspected in 2 of the 3 families as the most plausible factor to explain either the unusual recurrence of PAX6-related microphthalmia in the offspring of a healthy couple (Family 3, Figure 1C), or the remarkable inter-generational phenotypic variability between a proband and her father (Family 2, Figure 1B), respectively. In this sense, Sanger sequencing revealed some traces of the mutant alleles (c.120C>A or c.178T>C) in paternal blood samples, for which the peak heights were substantially lower than those of their heterozygous children. Surprisingly, a third case of potential mosaicism was suspected in the affected father of Family 1. This individual displayed a similar biased sequencing pattern of the mutant allele c.771G>A (Figure 1A). Moreover, unequal amplification of the mutant and wild-type alleles was evidenced in all the suspected mosaic individuals when SNaPshot was used (Figure 1). Haplotyping analysis confirmed paternity in the three families (data not shown).
FIGURE 1
Mosaicism was finally evaluated by ddPCR using allele-specific Taqman genotyping, which enabled us to obtain a more accurate assessment of the allele imbalance by quantifying the mutant allele fraction (AF) (Figure 1D). We confirmed the presence of somatic mosaic PAX6 alleles in these 3 individuals who showed variable AFs of 13–29% depending on the tested tissue (Figure 1E). As somatic mosaic variants were vertically transmitted to affected offspring in these families, we assumed that mutant alleles should also be present in the mosaic individuals in a relevant fraction of gonadal tissue. In this sense, we were able to confirm gonosomal mosaicism in the father of Family 2, detecting the mutant allele in gamete-forming cells at a ratio of 29%, as well as in several somatic tissues, such as blood, saliva, and urine cells, with a lower AF of 13%. As a result, we accurately established that the transmission risk of the variant p.(Cys40∗) in this family was about one-third. Unfortunately, sperm samples were unavailable in the other two mosaic fathers.
Overall, we have confirmed three cases of mosaicism in a cohort of 247 families with ODAs, representing a rate of 1.2%. Considering only aniridia, the mosaic rate is 3.8% with 2 families in a cohort of 78 families.
Phenotypic Variability Associated With Mosaic PAX6 Mutations
Table 1 summarizes all the currently available clinical data from mosaic fathers and their respective affected relatives. Fully heterozygous carriers of the nonsense PAX6 variants presented classical symptoms of congenital aniridia, including marked iris hypoplasia, photophobia, nystagmus, low visual acuity, as well as congenital or early-onset cataracts. Additional progressive ocular features such as glaucoma and AAK underlying limbal insufficiency were later developed. The proband of family 1, a 29-year-old female carrying the variant p.Trp257∗, also suffered from mild growth retardation in childhood. However, she showed no signs of ataxia or intellectual disability, both systemic features previously reported in a patient with this same mutation (). Surprisingly, her affected father (I:1) also suffered from congenital aniridia and cataracts, despite carrying the mutant allele in only 18% of his blood cells. Unlike the daughter, he presented an apparently milder disease outcome with no signs of AAK at 50 years of age. By contrast, the mosaic carrier of the variant p.Cys40∗ (Family 2, I:1), with a slightly lower grade of mosaicism (13%) in several somatic tissues, showed neither congenital aniridia nor any apparent serious visual impairment. He was only diagnosed with iris coloboma and cataracts in both eyes in the fourth decade of life, after the birth of his son, who had aniridia.
Table 1
| Family ID | Causing variant | Patient ID | Age | Genotype (mosaic AF) | Iris anomaly | Microphthalmia | Nystagmus | Congenital or early-onset cataracts | Glaucoma | Keratopathy | Other features |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | c.771G>A p.(Trp257∗) | I:1 (father) | 50 | Mosaic (18%, blood) | Complete aniridia (B) | + (B) | + (B) | + (B) | Cataract surgery | ||
| II:1 | 29 | HET | Complete aniridia (B) | + (B) | +(B) | + (B) | Limbal insufficiency (B) | Growth retardation: cataract surgery; amaurosis (RE) | |||
| 2 | c.120C>A p.(Cys40∗) | I:1 (father) | 59 | Mosaic (13%, blood, saliva, and urine; 29%, sperm) | Coloboma (B) | + (B) | |||||
| II:2 | 25 | HET | Complete aniridia (B) | + (B) | + (B) | + (B) | Corneal opacity with limbal insufficiency (B) | Surgical interventions for limbal transplantation and implantation of Ahmed glaucoma valve (RE); BCVA: FC/0.05. | |||
| 3 | c.178T>C p.(Tyr60His) | I:1 (father) | 80 | Mosaic (18%, blood; 29%, saliva) | Asymptomatic; no ocular features | ||||||
| II:1 | 43 | HET | + (B) | +(B) | + (B) | High hyperopia; secondary corectopia after iridectomy. | |||||
| II:2 | 38 | HET | + (B) | + (B) | + (B) | High hyperopia; secondary corectopia after iridectomy. | |||||
| III:1 | 10 | HET | + (B) | + (B) | + (B) | High hyperopia; secondary corectopia after iridectomy. | |||||
Genetic and clinical features of the families carrying postzygotic PAX6 variants.
Nucleotide numbering reflects cDNA in the reference sequence NM_000280.4 for PAX6. AF, allele fraction; B, bilateral; BCVA, best corrected visual acuity; FC, finger counting; HET, heterozygous; ID, identification; and RE, right eye.
The three heterozygous carriers of the missense p.(Tyr60His) variant presented a similar ocular phenotype of bilateral microphthalmia, congenital cataracts, nystagmus, and high hyperopia, without showing any systemic signs. Mosaicism was identified in the asymptomatic father (I:1, Family 3) of two affected siblings. Quantitative data from blood and buccal cells showed a relatively high mutant AF (18 and 29%, respectively). However, he has never complained of visual impairment, and his eyes were found to be normal in a thorough ophthalmic examination carried out in the 8th decade of life.
Discussion
Phenotypic variability is a well-established phenomenon for PAX6 defects (; ) that could be hypothetically attributable to genetic or epigenetic modifiers, pleiotropy, mosaicism, and/or gene dosage (; ; ; ; ; ). Here, we present 3 families from our Spanish cohort of ODAs manifesting distinctly inter-generational differences in disease severity and/or ocular phenotype. We confirmed that the variable expressivity observed in all of these families resulted from parental mosaic PAX6 mutations. Both families showed somatic mosaic alleles with a relatively high AF (> 10%) in healthy or mildly affected individuals and their vertical transmission to affected offspring, which suggests the existence of gonosomal PZVs. In one of them, gonosomal mosaicism was able to be assessed thanks to the availability of both somatic and gonadal samples, resulting in better estimation of the transmission risk of the mutation to future offspring. The estimated genetic risk of about one-third found in this family is quite higher than the risk level expected in a sporadic case carrying a de novo variant, which is usually considered to be negligible (). In the other two families, the exact risk could not be assessed due to the unavailability of sperm samples. However, both fathers likely carried the pathogenic PAX6 variant in a proportion of their germ line. Remarkably, the identification of mosaicism in an affected individual with aniridia, as we report here, involves modifying the initial genetic counseling, since the likelihood of recurrence is obviously lower than in heterozygous carriers. In view of our findings, parental mosaicism should be considered in sporadic cases with PAX6-associated diseases, even if parents do not show any ocular abnormalities.
In the two mosaic individuals carrying nonsense PAX6 mutations, similar levels of somatic mosaicism led to variable clinical outcomes ranging from congenital aniridia to considerably milder manifestations. Interestingly, we are the first to confirm low-level mosaicism in an affected individual clinically diagnosed with congenital aniridia but who manifested some apparently milder secondary ocular features compared to his fully heterozygous daughter. However, the mosaic father of a second family only showed minor iris defects that went unnoticed until adulthood. Therefore, mosaicism levels in blood are not a reliable indicator of the range and severity of ocular features. The variable phenotypic expression observed in these mosaic individuals could be influenced by different factors, including specific mutational effects, gene dosage, and lineage and timing-dependent PAX6 functionality, not only during ocular development but also in adult tissues (; ; ). In this sense, previous studies with transgenic and, more recently, genetically edited animal models confirmed that the patterning and differentiation of different ocular structures and cell lineages require different thresholds of PAX6 activity throughout eye embryogenesis (; ). Specifically, somatic PAX6 mosaicism in CRISPR-edited mouse embryos caused varying degrees of ODAs, as recently published (). Therefore, the identification of mosaic individuals for PAX6 mutations both in humans and animal models manifesting variable expressivity strongly reinforces the idea that PAX6 dosage plays a specific role in both eye development and phenotypic modulation. According to our findings and those reported using CRISPR models, somatic PAX6 mosaicism might explain some of the approximately 10% of patients with aniridia who apparently lack PAX6 mutations (; ; ) or even mild cases of ODAs (). The widespread use of more sensitive techniques, such as targeted deep sequencing and/or ddPCR, will allow for the identification of additional cases with somatic or gonosomal PZVs arising at early stages (). However, due to limitations on tissue sampling, it will remain challenging to detect PZVs with low AF that could appear later in embryonic development or those restricted to ocular tissues.
It has long been postulated that germline mosaicism in healthy parents could be the most likely explanation for the exceptional disease recurrence in affected siblings with no family history of aniridia (; ) or PAX6-related microphthalmia (; ). To date, this possibility has not been fully confirmed due to the limited availability of somatic and gonadal tissues for genetic testing. Here, we report an apparent autosomal dominant 3-generation family with microphthalmia in which we first assumed a reduced penetrance due to both disease recurrence in the first affected siblings and healthy parents. However, NGS analyses only revealed a novel likely pathogenic missense variant in PAX6, a highly penetrant gene. Similar missense mutations in the paired-domain of PAX6 have been occasionally reported to cause microphthalmia (; ; ; ); thus, this variant seemed to be the cause of the phenotype in the family. To delve deeper into the causes of this unusual disease recurrence, we exhaustively investigated the possibility of parental germline mosaicism in the unaffected first generation. In the asymptomatic father of this family, an unexpectedly high mutant AF was detected in several somatic tissues from ectoderm and endoderm lineages indicating that the mosaic PZV had to emerge early in the first embryonic cell divisions. Additionally, the lack of ocular signs in this mosaic individual suggests that the PAX6 activity had to reach an adequate threshold through optic cup morphogenesis. We could not discern whether this fact was related to a gene dosage effect underlying a lower mutant ratio in embryonic eye or if this variant is hypomorphic, similar to that described for other missense PAX6 variants (; ). Despite the rarity of PAX6-associated microphthalmia, with fewer than 10 variants described to date (), it is worth noting that disease recurrence has putatively been associated with mosaicism in a healthy progenitor in two additional families (; ). Thus, the possibility of PAX6 mosaicism should also be considered when explaining occurrence in two or more affected siblings with microphthalmia in the absence of family history.
Recent evidence has suggested that transmission of parental mosaicism could explain up to 10% of apparently de novo mutations in some pathologies, and thus mosaicism rates might be higher than previously expected (; ). In our cohort of patients with aniridia, mosaic PZVs were identified in at least 3.8% of families, though this rate is likely underestimated. We cannot rule out that some of our patients without PAX6 mutations or some parents of de novo cases might present a low-grade of mosaicism. Therefore, larger systematic studies should be carried out using high-sensitivity ultradeep sequencing, single cell analysis or ddPCR in several somatic tissues to obtain a better estimation of the actual mosaicism rate as well as to elucidate the actual relevance of PZVs in the pathogenesis of PAX6-associated diseases.
In brief, our work confirms the long-held hypothesis of germinal mosaicism in aniridia to explain disease recurrence in the offspring of healthy parents. Additionally, we demonstrate for the first time that mosaic PAX6 variants cause phenotypic variability from congenital aniridia, mild forms of isolated iris coloboma, and even asymptomatic individuals. Consequently, our findings have important clinical implications for genetic counseling and ophthalmic management in congenital aniridia and related developmental eye disorders. Finally, somatic and/or gonosomal mosaicism should be taken into consideration as genetic factors to explain not only extraordinary cases of co-occurrence in siblings but also intra-familial variable expressivity, as well as some of apparently de novo cases and even uncharacterized PAX6-negative cases in aniridia.
Statements
Author contributions
MC and MM contributed the conception and design of the study. MT, MM, PR, and CV performed genetic analyses. MT, MM, PR, M-AM-P, and MV participated in the analysis and interpretation of genetic data for the work. MG, FB-K, DR-Z, GR, FM-N, ST-S, BG, and CA participated in the recruitment, clinical evaluation, and interpretation of clinical data. MC wrote the first draft of the manuscript. MT, MM, and MV wrote and/or prepared sections of the manuscript. All authors contributed to manuscript revision, reading and approving the submitted version.
Funding
This work was supported by Spanish Institute of Health Carlos III (ISCIII) and Spanish Ministry of Economy and Competitiveness funding partially supported by the following European Regional Development Funds (ERDF): PI17/01164 and SAF2013-46943-R (to MC), PI14/0948 and PI17/01659 (to M-AM-P), the Spanish Center for Biomedical Network Research on Rare Diseases (CIBERER, 06/07/0036 grant, to CA and M-AM-P); by Regional Government of Madrid (CAM, B2017/BMD3721) (to CA and M-AM-P), the Spanish National Organization of the Blind (ONCE) (to MV), the Mutua Madrileña Foundation and the Spanish Foundation of Rare Diseases (FEDER) (to MC), the University Chair UAM-IIS-FJD of Genomic Medicine, and the Ramon Areces Foundation (to CA). MC was supported by the ISCIII Miguel Servet Program (CP12/03256 and CPII17/00006) and MT was supported by a Ph.D. fellowship from the Conchita Rábago Foundation.
Acknowledgments
The authors thank the families for their participation in this study, the Spanish Association of Aniridia for its helpful support with patient sampling and Oliver Shaw for writing assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
1.^http://cadd.gs.washington.edu/
2.^http://bejerano.stanford.edu/mcap/
3.^http://gnomad.broadinstitute.org/
References
1
Acuna-HidalgoR.BoT.KwintM. P.van de VorstM.PinelliM.VeltmanJ. A.et al (2015). Post-zygotic point mutations are an underrecognized source of de novo genomic variation.Am. J. Hum. Genet.9767–74. 10.1016/j.ajhg.2015.05.008
2
Acuna-HidalgoR.VeltmanJ. A.HoischenA. (2016). New insights into the generation and role of de novo mutations in health and disease.Genome Biol.17:241. 10.1186/s13059-016-1110-110.1186/s13059-016-1110-1
3
AnsariM.RaingerJ.HansonI. M.WilliamsonK. A.SharkeyF.HarewoodL.et al (2016). Genetic analysis of ‘PAX6-Negative’ individuals with Aniridia or Gillespie syndrome.PLoS One11:e0153757. 10.1371/journal.pone.0153757
4
AzumaN.YamaguchiY.HandaH.TadokoroK.AsakaA.KawaseE.et al (2003). Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations.Am. J. Hum. Genet.721565–1570. 10.1086/375555
5
BeryozkinA.LevyG.BlumenfeldA.MeyerS.NamburiP.MoradY.et al (2016). Genetic analysis of the Rhodopsin gene identifies a mosaic dominant retinitis Pigmentosa mutation in a healthy individual.Invest. Ophthalmol. Vis. Sci.57940–947. 10.1167/iovs.15-18702
6
Blanco-KellyF.PalomaresM.VallespinE.VillaverdeC.Martin-ArenasR.Velez-MonsalveC.et al (2017). Improving molecular diagnosis of aniridia and WAGR syndrome using customized targeted array-based CGH.PLoS One12:e0172363. 10.1371/journal.pone.0172363
7
Blanco-KellyF.Villaverde-MonteroC.Lorda-SanchezI.MillanJ. M.Trujillo-TiebasM. J.AyusoC. (2013). Guidelines for genetic study of aniridia.Arch. Soc. Esp. Oftalmol.88145–152. 10.1016/j.oftal.2012.07.006S0365-6691(12)00384-X
8
BobilevA. M.McDougalM. E.TaylorW. L.GeisertE. E.NetlandP. A.LauderdaleJ. D. (2016). Assessment of PAX6 alleles in 66 families with aniridia.Clin. Genet.89669–677. 10.1111/cge.12708
9
CeroniF.Aguilera-GarciaD.ChassaingN.BaxD. A.Blanco-KellyF.RamosP.et al (2018). New GJA8 variants and phenotypes highlight its critical role in a broad spectrum of eye anomalies.Hum. Genet.10.1007/s00439-018-1875-2[Epub ahead of print].
10
ChassaingN.CausseA.VigourouxA.DelahayeA.AlessandriJ. L.Boespflug-TanguyO.et al (2013). Molecular findings and clinical data in a cohort of 150 patients with anophthalmia/microphthalmia.Clin. Genet.86326–334. 10.1111/cge.12275
11
ChouC. M.NelsonC.TarleS. A.PribilaJ. T.BardakjianT.WoodsS.et al (2015). Biochemical basis for dominant inheritance, variable penetrance, and maternal effects in RBP4 congenital eye disease.Cell161634–646. 10.1016/j.cell.2015.03.006
12
CveklA.CallaertsP. (2017). PAX6: 25th anniversary and more to learn.Exp. Eye Res.15610–21. 10.1016/j.exer.2016.04.017
13
DansaultA.DavidG.SchwartzC.JaliffaC.VieiraV.de la HoussayeG.et al (2007). Three new PAX6 mutations including one causing an unusual ophthalmic phenotype associated with neurodevelopmental abnormalities.Mol. Vis.13511–523.
14
Davis-SilbermanN.KalichT.Oron-KarniV.MarquardtT.KroeberM.TammE. R.et al (2005). Genetic dissection of Pax6 dosage requirements in the developing mouse eye.Hum. Mol. Genet.142265–2276. 10.1093/hmg/ddi231
15
DemlB.ReisL. M.LemyreE.ClarkR. D.KariminejadA.SeminaE. V. (2016). Novel mutations in PAX6, OTX2 and NDP in anophthalmia, microphthalmia and coloboma.Eur. J. Hum. Genet.24535–541. 10.1038/ejhg.2015.155ejhg2015155
16
DubeyS. K.MahalaxmiN.VijayalakshmiP.SundaresanP. (2015). Mutational analysis and genotype-phenotype correlations in southern Indian patients with sporadic and familial aniridia.Mol. Vis.2188–97.
17
ErezA.LiJ.GeraghtyM. T.Ben-ShacharS.CooperM. L.MensingD. E.et al (2010). Mosaic deletion 11p13 in a child with dopamine beta-hydroxylase deficiency–case report and review of the literature.Am. J. Med. Genet. A152A, 732–736. 10.1002/ajmg.a.33269
18
FaivreL.WilliamsonK. A.FaberV.LaurentN.GrimaldiM.Thauvin-RobinetC.et al (2006). Recurrence of SOX2 anophthalmia syndrome with gonosomal mosaicism in a phenotypically normal mother.Am. J. Med. Genet. A140636–639. 10.1002/ajmg.a.31114
19
GrazianoC.D’EliaA. V.MazzantiL.MoscanoF.Guidelli GuidiS.ScaranoE.et al (2007). A de novo nonsense mutation of PAX6 gene in a patient with aniridia, ataxia, and mental retardation.Am. J. Med. Genet. A143A, 1802–1805. 10.1002/ajmg.a.31808
20
Gregory-EvansC. Y.WangX.WasanK. M.ZhaoJ.MetcalfeA. L.Gregory-EvansK. (2014). Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.J. Clin. Invest.124111–116. 10.1172/JCI7046270462
21
GronskovK.RosenbergT.SandA.Brondum-NielsenK. (1999). Mutational analysis of PAX6: 16 novel mutations including 5 missense mutations with a mild Aniridia phenotype.Eur. J. Hum. Genet.7274–286. 10.1038/sj.ejhg.5200308
22
GuptaS. K.De BeckerI.TremblayF.GuernseyD. L.NeumannP. E. (1998). Genotype/phenotype correlations in Aniridia.Am. J. Ophthalmol.126203–210. 10.1016/S0002-9394(98)00191-3
23
HansonI.ChurchillA.LoveJ.AxtonR.MooreT.ClarkeM.et al (1999). Missense mutations in the most ancient residues of the PAX6 paired domain underlie a spectrum of human congenital eye malformations.Hum. Mol. Genet.8165–172. 10.1093/hmg/8.2.165
24
HingoraniM.HansonI.van HeyningenV. (2012). Aniridia.Eur. J. Hum. Genet.201011–1017. 10.1038/ejhg.2012.100ejhg2012100
25
HuynhM. T.Boudry-LabisE.DubanB.AndrieuxJ.TranC. T.TampereH.et al (2017). WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion.Am. J. Med. Genet. A1731690–1693. 10.1002/ajmg.a.38206
26
JiaX.GuoX.XiaoX.LiS.ZhangQ. (2010). A novel mutation of PAX6 in Chinese patients with new clinical features of Peters’ anomaly.Mol. Vis.16676–681.
27
LeeH. J.ColbyK. A. (2013). A review of the clinical and genetic aspects of Aniridia.Semin. Ophthalmol.28306–312. 10.3109/08820538.2013.825293
28
MyersC. T.HollingsworthG.MuirA. M.SchneiderA. L.ThuesmunnZ.KnuppA.et al (2018). Parental mosaicism in “De Novo” epileptic encephalopathies.N. Engl. J. Med.3781646–1648. 10.1056/NEJMc1714579
29
NallathambiJ.NeethirajanG.ShashikantS.VijayalakshmiP.SundaresanP. (2006). PAX6 missense mutations associated in patients with optic nerve malformation.Mol. Vis.12236–242.
30
NetlandP. A.ScottM. L.BoyleJ. W. T.LauderdaleJ. D. (2011). Ocular and systemic findings in a survey of aniridia subjects.J. AAPOS15562–566. 10.1016/j.jaapos.2011.07.009
31
PatelN.KhanA. O.AlsahliS.Abdel-SalamG.NowilatyS. R.MansourA. M.et al (2018). Genetic investigation of 93 families with microphthalmia or posterior microphthalmos.Clin. Genet.931210–1222. 10.1111/cge.13239
32
ReedT. E.FallsH. F. (1955). A pedigree of aniridia with a discussion of germinal mosaicism in man.Am. J. Hum. Genet.728–38.
33
RieraM.WertA.NietoI.PomaresE. (2017). Panel-based whole exome sequencing identifies novel mutations in microphthalmia and anophthalmia patients showing complex Mendelian inheritance patterns.Mol. Genet. Genomic Med.5709–719. 10.1002/mgg3.329
34
RobinsonD. O.HowarthR. J.WilliamsonK. A.van HeyningenV.BealS. J.CrollaJ. A. (2008). Genetic analysis of chromosome 11p13 and the PAX6 gene in a series of 125 cases referred with aniridia.Am. J. Med. Genet. A146A, 558–569. 10.1002/ajmg.a.32209
35
SannanN. S.Gregory-EvansC. Y.LyonsC. J.LehmanA. M.LangloisS.WarnerS. J.et al (2017). Correlation of novel PAX6 gene abnormalities in aniridia and clinical presentation.Can. J. Ophthalmol.52570–577. 10.1016/j.jcjo.2017.04.006
36
SchedlA.RossA.LeeM.EngelkampD.RashbassP.van HeyningenV.et al (1996). Influence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities.Cell8671–82. 10.1016/S0092-8674(00)80078-1
37
ShahamO.MenuchinY.FarhyC.Ashery-PadanR. (2012). Pax6: a multi-level regulator of ocular development.Prog. Retin. Eye Res.31351–376. 10.1016/j.preteyeres.2012.04.002
38
SkeensH. M.BrooksB. P.HollandE. J. (2011). Congenital Aniridia variant: minimally abnormal irides with severe limbal stem cell deficiency.Ophthalmology1181260–1264. 10.1016/j.ophtha.2010.11.021
39
StosserM. B.LindyA. S.ButlerE.RettererK.Piccirillo-StosserC. M.RichardG.et al (2017). High frequency of mosaic pathogenic variants in genes causing epilepsy-related neurodevelopmental disorders.Genet. Med.20403–410. 10.1038/gim.2017.114
40
TangH. K.ChaoL. Y.SaundersG. F. (1997). Functional analysis of paired box missense mutations in the PAX6 gene.Hum. Mol. Genet.6381–386. 10.1093/hmg/6.3.381
41
ThomasS.ThomasM. G.AndrewsC.ChanW. M.ProudlockF. A.McLeanR. J.et al (2014). Autosomal-dominant nystagmus, foveal hypoplasia and presenile cataract associated with a novel PAX6 mutation.Eur. J. Hum. Genet.22344–349. 10.1038/ejhg.2013.162
42
van HeyningenV.WilliamsonK. A. (2002). PAX6 in sensory development.Hum. Mol. Genet.111161–1167. 10.1093/hmg/11.10.1161
43
VasilyevaT. A.VoskresenskayaA. A.Kasmann-KellnerB.KhlebnikovaO. V.PozdeyevaN. A.BayazutdinovaG. M.et al (2017). Molecular analysis of patients with Aniridia in Russian federation broadens the spectrum of PAX6 mutations.Clin. Genet.92639–644. 10.1111/cge.13019
44
VincentM. C.PujoA. L.OlivierD.CalvasP. (2003). Screening for PAX6 gene mutations is consistent with haploinsufficiency as the main mechanism leading to various ocular defects.Eur. J. Hum. Genet.11163–169. 10.1038/sj.ejhg.52009405200940
45
YasueA.KonoH.HabutaM.BandoT.SatoK.InoueJ.et al (2017). Relationship between somatic mosaicism of Pax6 mutation and variable developmental eye abnormalities-an analysis of CRISPR genome-edited mouse embryos.Sci. Rep.7:53.
Summary
Keywords
parental mosaicism, PAX6, aniridia, variable expressivity, microphthalmia, post-zygotic variants
Citation
Tarilonte M, Morín M, Ramos P, Galdós M, Blanco-Kelly F, Villaverde C, Rey-Zamora D, Rebolleda G, Muñoz-Negrete FJ, Tahsin-Swafiri S, Gener B, Moreno-Pelayo M-A, Ayuso C, Villamar M and Corton M (2018) Parental Mosaicism in PAX6 Causes Intra-Familial Variability: Implications for Genetic Counseling of Congenital Aniridia and Microphthalmia. Front. Genet. 9:479. doi: 10.3389/fgene.2018.00479
Received
10 August 2018
Accepted
26 September 2018
Published
17 October 2018
Volume
9 - 2018
Edited by
Yuk Fai Leung, Purdue University, United States
Reviewed by
Zi-Bing Jin, Wenzhou Medical University, China; Larry Baum, The University of Hong Kong, Hong Kong
Updates
Copyright
© 2018 Tarilonte, Morín, Ramos, Galdós, Blanco-Kelly, Villaverde, Rey-Zamora, Rebolleda, Muñoz-Negrete, Tahsin-Swafiri, Gener, Moreno-Pelayo, Ayuso, Villamar and Corton.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Manuela Villamar, taugen.hrc@salud.madrid.org Marta Corton, mcorton@fjd.es
†These authors have contributed equally to this work
This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.